We certainly think that this might be the case, particularly if you consider HSH’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as KBIO has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.
KALOBIOS PHARMACEUTICALS INC (KBIO): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry